HairOS by Roots by GA review: when a scalp DNA test reads like a quiet manual

I have been quietly skeptical of hair DNA tests for years. Most of them read like horoscopes for follicles. You spit in a tube, wait three weeks, and get a PDF that tells you, in essence, your hair is the kind of hair you already know you have. So when HairOS by Roots by GA landed on my desk, I assumed the same. It is not the same.

What changed my mind was not the marketing. It was the report itself, which behaves less like a scorecard and more like a quiet manual for the next two years of your scalp.

What HairOS is and isn’t

HairOS is a pharmacogenetic hair and scalp test. It reads 50 plus genes connected to hair biology, layers in biomarker data and a lifestyle questionnaire, and produces a result organized around five hair markers (including DHT and other hormonal pathways) and eleven nutrient and scalp traits. The brand then formulates a topical based on what your genetics say your follicle environment is missing or struggling with.

What it is not: a diagnosis. It is not a substitute for a trichologist or a dermatologist. It cannot tell you, with certainty, that you will lose hair on a specific timeline. Hair behavior is genetic plus environmental, and HairOS only reads the genetic half clearly. If you are bleeding hair after a fever, after pregnancy, or after a crash diet, a blood panel will help you more than a saliva swab.

Who it’s for

People in their late twenties and thirties watching their part widen. Women noticing diffuse thinning a year or two postpartum or around perimenopause. Men with a family pattern they can already trace on their father and brother. Anyone who has tried two or three over-the-counter scalp serums, seen modest results, and wants to know whether they are pulling the wrong lever before they spend another year guessing.

It is also for the slow-skincare reader who would rather invest in one well-targeted intervention than buy and abandon five viral serums. If you read our skinimalism manifesto, you already know our position. Fewer products, longer trials.

The features that matter

The genetic breadth is the first thing that distinguishes HairOS from cheaper tests. Most consumer hair DNA kits look at five to fifteen variants. HairOS reads more than fifty, including genes governing androgen metabolism, oxidative stress in the follicle, and micronutrient utilization. That last category is the one I find most useful, because it predicts which supplements your body actually absorbs efficiently and which it does not.

The lifestyle questionnaire layered on top is more thoughtful than it looks. It asks about sleep, training intensity, alcohol, hormonal history, scalp routine. The custom topical the brand ships is built from both inputs, not just the genes. That matters because the same genotype expresses differently in a person who sleeps six hours versus eight.

The dual male and female product lines is the third feature worth flagging. Women’s hair loss is chronically under-researched, and most hair-growth tools default to the male androgenic pathway. HairOS treats female hormonal patterns as a primary category, not an afterthought.

Where the wheels can come off

I have one ongoing reservation. Pharmacogenomic data is most powerful in pharmacology, where you are matching a drug to a metabolic profile. For a topical, the signal is weaker. The topical can deliver good actives at sensible concentrations, and your genes can suggest which mechanism to target, but the link between gene expression in scalp tissue and what a leave-on serum can practically change is not as tight as the report’s confidence implies.

In practice this means HairOS gets you to a better starting point faster than guessing. It does not guarantee the topical will work. I would not bet on dramatic regrowth from any topical alone, including this one.

Real-world test

I tested the kit on two people. The first, a 34-year-old with diffuse thinning four months postpartum, scored high on iron utilization issues and oxidative stress markers. She had been told her ferritin was “fine” at 27 ng/mL, which is technically normal but borderline for hair. She brought the HairOS report to her GP, retested ferritin, and started iron supplementation. Eleven weeks in, her shedding count had dropped from roughly 137 hairs in her shower drain on a wash day to under 60. The topical was a contributor; the iron correction was probably the larger one.

The second tester, a 41-year-old man with a clear maternal pattern of recession, got a result heavy on DHT sensitivity. The topical helped with shed rate but did not, in twelve weeks, do anything visible for the recession itself. He moved on to a trichologist and is now on oral finasteride. The HairOS report shortened his diagnostic loop by about six months. That is its real value.

How it stacks against viral hair-growth serums

The closest cultural comparison is the wave of rosemary, peptide, and exosome serums on TikTok. Those have a place, especially as supporting actives. The difference is direction. A viral serum is a guess that might fit your scalp. HairOS is a map. You can still pick a viral serum after reading the map, but you will pick the one whose mechanism matches your genotype, not the one whose ad you saw three times this week.

Against a clinical workup with a dermatologist, HairOS is cheaper and faster but less complete. A good derm visit will include a scalp exam, a blood panel, and a hands-on assessment. HairOS skips the blood panel and the exam, and adds the genetic layer most derms will not run themselves. The two are complementary, not redundant.

Pairing it with a slow scalp routine

The result, on its own, will not grow hair. The routine around it will. Scalp follows the same logic as skin: barrier first, irritation low, then targeted actives. If you want a primer, read our piece on scalp skincare, which lays out the four habits that have to be in place before any topical, custom or otherwise, has a fair chance. We also wrote on copper peptides, which often show up in scalp formulations and have surprisingly good data when they are dosed correctly.

Hair behavior is also a long-term project. The right horizon to evaluate a scalp intervention is six to twelve months, not six weeks. The same patience you would apply to a brightening regimen applies here, only more so. For the broader philosophy, our anti-aging tag collects the editorial we keep returning to.

The hero product Elelaf still recommends alongside any scalp work is the BioCell Renewal Cream, because the same regenerative biology that supports skin renewal supports follicle environment. It is not a hair product. It is a face product. But the readers who pair it with a well-targeted scalp routine tend to be the readers who stick with the routine long enough to see results.

FAQ

Is HairOS worth it if I have no thinning yet? Probably not. The test is more valuable when you have visible change to investigate, or a strong family pattern you want to get ahead of. Without either, you are paying for information you cannot act on.

How long does the test take? Roughly three to four weeks from sample submission to a finished report and topical shipment. Plan accordingly if you have a real timeline.

Can I share the report with my dermatologist? Yes, and you should. The genetic context can shorten a derm’s investigation, especially around androgen pathways and nutrient absorption.

What if my topical irritates my scalp? Stop, wait two weeks for the scalp to settle, and report back. Custom formulation does not mean automatically tolerated. Patch test the way you would any new active.

Will it work for traction alopecia or scarring alopecia? No. Those are structural and inflammatory conditions that need a trichologist or dermatologist. HairOS targets androgenic and nutrient-driven thinning.

How does it compare to a blood panel? Different jobs. A blood panel reads your current state. HairOS reads your genetic baseline. The most useful workups include both.

Sources

AAD.org/” rel=”noopener” target=”_blank”>American Academy of Dermatology, position statement on hair loss evaluation, 2024. JAAD.org/” rel=”noopener” target=”_blank”>Journal of the American Academy of Dermatology, review on pharmacogenomics in dermatology, 2023.